Form4insider filings, from the source

SEC Form 4 · accession 0001104659-16-131586

Syros Pharmaceuticals, Inc. · SYRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Amir Nashat
Director · 10% Owner
Period of report
Jul 6, 2016
Accepted (ET)
Jul 7, 2016 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jul 6, 2016C1,164,486—A1,164,486ISee Footnote
Common StockF1,F3Jul 6, 2016C22,167—A22,167ISee Footnote
Common StockF2Jul 6, 2016P373,847$12.50A1,538,333ISee Footnote
Common StockF3Jul 6, 2016P26,153$12.50A48,320ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series B Preferred StockF2,F1—Jul 6, 2016C4,366,825D——Common Stock1,164,4860I
Series B Preferred StockF3,F1—Jul 6, 2016C83,129D——Common Stock22,1670I

Explanation of responses